Evidence mapPaperPMID 36577032Full record

ArticleDiabetes care2023

Circulating Small Noncoding RNA Profiling as a Potential Biomarker of Atherosclerotic Plaque Composition in Type 1 Diabetes.

Alessandra Giannella, Esmeralda Castelblanco, Carlo Federico Zambon, Daniela Basso, Marta Hernandez, Emilio Ortega, Nuria Alonso, Didac Mauricio, Angelo Avogaro, Giulio Ceolotto and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Diabetes care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. MicroRNAs in diabetic macroangiopathy.Cardiovascular diabetology · 2024
    Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 3 countries.

Alessandra Giannella1Department of Medicine, University of Padova, Padova, Italy.
Esmeralda Castelblanco2Division of Endocrinology, Metabolism and Lipid Research, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO.
Carlo Federico Zambon1Department of Medicine, University of Padova, Padova, Italy.
Daniela Basso1Department of Medicine, University of Padova, Padova, Italy.
Marta Hernandez4Department of Endocrinology & Nutrition, Hospital Arnau de Vilanova and Institut d'Investigació Biomédica de Lleida, Lleida, Spain.
Emilio Ortega5Department of Endocrinology & Nutrition, Diabetes Unit, Hospital Clínic de Barcelona, Barcelona, Spain.
Nuria Alonso8Department of Endocrinology and Nutrition, Health Sciences Research Institute and University Hospital Germans Trias i Pujol, Badalona, Spain.
Didac Mauricio3Unitat de Suport a la Recerca Barcelona, Institut Universitari d'Investigació en Atenció Primària Jordi Gol i Gurina, Barcelona, Spain.ORCID 0000-0002-2868-0250
Angelo Avogaro1Department of Medicine, University of Padova, Padova, Italy.ORCID 0000-0002-1177-0516
Giulio Ceolotto1Department of Medicine, University of Padova, Padova, Italy.ORCID 0000-0002-4687-8033
Saula Vigili de Kreutzenberg1Department of Medicine, University of Padova, Padova, Italy.
University of Padua · ITCentro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas · ESHospital Universitari Arnau de Vilanova · ESInstituto de Salud Carlos III · ESUniversitat de Vic - Universitat Central de Catalunya · ESWashington University in St. Louis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveCardiovascular disease (CVD) accounts for most deaths in patients with type 1 diabetes (T1D); however, the determinants of plaque composition are unknown. miRNAs regulate gene expression, participate in the development of atherosclerosis, and represent promising CVD biomarkers. This study analyzed the circulating miRNA expression profile in T1D with either carotid calcified (CCP) or fibrous plaque (CFP). RESEARCH DESIGN AND

methodsCirculating small noncoding RNAs were sequenced and quantified using next-generation sequencing and bioinformatic analysis in an exploratory set of 26 subjects with T1D with CCP and in 25 with CFP. Then, in a validation set of 40 subjects with CCP, 40 with CFP, and 24 control subjects with T1D, selected miRNA expression was measured by digital droplet PCR. Putative gene targets enriched for pathways implicated in atherosclerosis/vascular calcification/diabetes were analyzed. The patients' main clinical characteristics were also recorded.

resultsmiR-503-5p, let-7d-5p, miR-106b-3p, and miR-93-5p were significantly upregulated, while miR-10a-5p was downregulated in patients with CCP compared with CFP (all fold change >±1.5; P < 0.05). All candidate miRNAs showed a significant correlation with LDL-cholesterol, direct for the upregulated and inverse for the downregulated miRNA, in CCP. Many target genes of upregulated miRNAs in CCP participate in osteogenic differentiation, apoptosis, inflammation, cholesterol metabolism, and extracellular matrix organization.

conclusionsThese findings characterize miRNAs and their signature in the regulatory network of carotid plaque phenotype in T1D, providing new insights into plaque pathophysiology and possibly novel biomarkers of plaque composition.

Indexed as

AtherosclerosisDiabetes Mellitus, Type 1MicroRNAsPlaque, AtheroscleroticRNA, Small UntranslatedBiomarkersCholesterolHumansOsteogenesisBiomarkersCholesterolMicroRNAsRNA, Small Untranslated

Identifiers

PMID36577032
PMCPMC10020028
OpenAlexW4313207119

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.